Summary & Overview
HCPCS Level II J9308: Injection of Ramucirumab, 5 mg
HCPCS Level II code J9308 represents an injection of ramucirumab, 5 mg, a targeted monoclonal antibody used in oncology care. Nationally, accurate reporting of this HCPCS Level II code supports claims processing, therapy tracking, and payment for infusion-based cancer treatments. This code matters for facilities that administer biologic oncology agents in outpatient infusion centers and hospital outpatient departments.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how the code is used clinically, typical sites of service, and payer coverage considerations. The publication summarizes benchmark metrics where available, recent policy or reimbursement updates that affect biologic infusion coding, and clinical context for use of ramucirumab.
The content provides practical reference information for coding, claims submission, and billing workflows tied to J9308, together with links to related codes and guidance when available. Data not available in the input will be flagged accordingly in detailed sections.
Billing Code Overview
HCPCS Level II code J9308 describes an injection of ramucirumab, 5 mg. This code is used to report administration of the specified biologic medication. The service type is injectable biologic therapy, and the typical site of service is outpatient infusion centers or hospital outpatient departments where intravenous or parenteral oncology therapies are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient receiving intravenous ramucirumab for advanced or metastatic solid tumors such as gastric, gastroesophageal junction, or non-small cell lung carcinoma. The patient presents to an outpatient infusion center or hospital outpatient department for scheduled systemic anticancer therapy. After pre-infusion assessment (vital signs, review of labs including liver function and blood counts, and verification of informed consent), the infusion nurse or oncology pharmacist prepares ramucirumab per weight-based or dose-based orders. The medication J9308 (ramucirumab, 5 mg) is administered via intravenous infusion, typically with premedication as indicated and infusion-related monitoring for hypertension, proteinuria, bleeding, or infusion reactions. Post-infusion observation and documentation of administered lot numbers, dose, and patient tolerance occur before discharge. Typical sites of service are outpatient infusion centers, hospital outpatient departments, and occasionally physician offices with infusion capability.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | When a portion of a single-use vial of ramucirumab is discarded after preparation |